Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22911089 | 0.92 | HCRTR1 (0.34) | PDK2PTGER4LRRK2 | |
| SCHEMBL22910860 | 0.91 | PDK2 (0.33) | PDK2TTKHPGDLRRK2 | |
| SCHEMBL16759899 | 0.91 | FASN (0.37) | PDK2FASNGRM4MAPK1PTGER4 | |
| SCHEMBL22911080 | 0.91 | FASN (0.37) | PDK2FASNGRM4MAPK1PTGER4 | |
| SCHEMBL22910813 | 0.89 | PDK2 (0.36) | PDK2PTGER4TTKHPGDAXL | |
| SCHEMBL22911081 | 0.89 | CNR2 (0.37) | — | |
| SCHEMBL22910879 | 0.89 | ATXN2 (0.33) | PDK2 | |
| SCHEMBL22911021 | 0.89 | PDK2 (0.36) | PDK2FASNPTGER4TTKRAB9A | |
| SCHEMBL22911094 | 0.83 | MGLL (0.38) | PDK2 | |
| SCHEMBL22911091 | 0.83 | LRRK2 (0.37) | HPGDLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | PDK2 984/4885FASN 2871/4885GRM4 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.